SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000921895-23-000754
Filing Date
2023-03-23
Accepted
2023-03-23 16:45:46
Documents
2

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO THE SCHEDULE 13D sc13da207609011_03232023.htm SC 13D/A 142533
2 AMENDMENT TO THE COOPERATION AGREEMENT, DATED MARCH 21, 2023 ex991to13da207609011_032323.pdf SC 13D/A 184636
  Complete submission text file 0000921895-23-000754.txt   398771
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Subject) CIK: 0000949858 (see all company filings)

IRS No.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-45969 | Film No.: 23756811
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 119 ROWAYTON AVENUE 2ND FLOOR NORWALK CT 06853
Business Address 119 ROWAYTON AVENUE 2ND FLOOR NORWALK CT 06853 212-230-3220
DIALECTIC CAPITAL MANAGEMENT, LP (Filed by) CIK: 0001411512 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A